Form 4: Akari Therapeutics Director Acquires Shares and Warrants in Private Placement

Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, acquired 1,326,258,000 ordinary shares and accompanying warrants in a private placement on May 31, 2024.

Summary

• Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, filed a Form 4 disclosing changes in beneficial ownership.
• On May 31, 2024, Mr. Prudo-Chlebosz acquired 1,326,258,000 ordinary shares and accompanying warrants in a private placement.
• The purchase price was $0.0009425 per ordinary share and accompanying warrant.
• The warrants allow the purchase of up to 1,326,258,000 ordinary shares at an exercise price of $0.000895 per share.
• Mr. Prudo-Chlebosz also holds shares indirectly through Praxis Trustees Limited and RPC Pharma Limited.
• A Power of Attorney was executed on December 13, 2023, appointing Rachelle Jacques and Wendy F. DiCicco as attorneys-in-fact.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard insider transaction. The director's investment could be seen as a positive signal, but it's a routine filing.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's increased investment in the company.

Stakeholder Impact

• The acquisition of shares by a director may be viewed positively by shareholders, potentially signaling confidence in the company's future.

Key Dates